Advertisement

Tumor Biology

, Volume 37, Issue 7, pp 9755–9769 | Cite as

The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines

  • Ying-Ying Wang
  • Xiao-Ling Gu
  • Chao Wang
  • Hua Wang
  • Qi-Chao Ni
  • Chun-Hui Zhang
  • Xia-Fei Yu
  • Li-Yi Yang
  • Zhi-Xian He
  • Guo-Xin Mao
  • Shu-Yun Yang
Original Article

Abstract

Far-upstream element (FUSE)-binding protein 2 (FBP2) was a member of single-stranded DNA-binding protein family; it played an important role in regulating transcription and post-transcription and is involved in the regulation of C-MYC gene expression in liver tumors. However, the role of FBP2 in breast cancer and its mechanism has not been studied yet. Here, we discovered that FBP2 was up-regulated in breast cancer tissues and breast cancer cell lines. Moreover, immunohistochemistry analysis demonstrated that up-regulated FBP2 was highly associated with tumor grade, Ki-67, and poor prognosis, which was an independent prognostic factor for survival of breast cancer patients. At the cellular level, we found that FBP2 was correlated with cell cycle progression by accelerating G1/S transition, and knockdown of FBP2 could weaken cell proliferation, anchorage-independent cell growth, while enhancing the sensitivity of breast cancer cells to doxorubicin. More importantly, we found that activation of PI3K/AKT pathway could phosphorylate FBP2, and then make FBP2 shuttle from cytoplasm into the nucleus, which was the main mechanism of breast cancer cell proliferation and drug resistance. Taken together, our findings supported the notion that FBP2 might via PI3K/AKT pathway influence breast cancer progression and drug resistance, which might provide a new target for the design of anti-cancer drugs for breast cancer patients.

Keywords

Breast cancer FBP2 Proliferation Prognosis Doxorubicin Resistance 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (grants no. 81302285, no. 81472185) and The Natural Science Foundation of Nantong University (no. 12Z009).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefPubMedGoogle Scholar
  3. 3.
    Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011;30(43):4437–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRefGoogle Scholar
  5. 5.
    Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21):5856–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012;323(1):77–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, et al. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013;328(2):353–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Singh BN, Kumar D, Shankar S, Srivastava RK. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol. 2012;84(9):1154–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7(8):1315–26.CrossRefPubMedGoogle Scholar
  10. 10.
    De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17–27.CrossRefPubMedGoogle Scholar
  11. 11.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Pan D, Liu B, Jin X, Zhu J. IL-7 splicing variant IL-7delta5 induces human breast cancer cell proliferation via activation of PI3K/Akt pathway. Biochem Biophys Res Commun. 2012;422(4):727–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-beta signaling axes. Cancer Discov. 2012;2(3):248–59.CrossRefPubMedGoogle Scholar
  14. 14.
    Goler-Baron V, Sladkevich I, Assaraf YG. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 2012;83(10):1340–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Davis-Smyth T, Duncan RC, Zheng T, Michelotti G, Levens D. The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J Biol Chem. 1996;271(49):31679–87.CrossRefPubMedGoogle Scholar
  16. 16.
    Kroll TT, Zhao WM, Jiang C, Huber PW. A homolog of FBP2/KSRP binds to localized mRNAs in Xenopus oocytes. Development. 2002;129(24):5609–19.CrossRefPubMedGoogle Scholar
  17. 17.
    Rydziel S, Delany AM, Canalis E. AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J Biol Chem. 2004;279(7):5397–404.CrossRefPubMedGoogle Scholar
  18. 18.
    Gherzi R, Lee KY, Briata P, Wegmuller D, Moroni C, Karin M, et al. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell. 2004;14(5):571–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics. 2008;8(23-24):5086–96.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang F, Tian Q, Wang Y. Far upstream element-binding protein 1 (FUBP1) is overexpressed in human gastric cancer tissue compared to non-cancerous tissue. Onkologie. 2012;36(11):650–5.Google Scholar
  21. 21.
    Baumgarten P, Harter PN, Tonjes M, Capper D, Blank AE, Sahm F, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2):205–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 2009;69(6):2234–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 2008;8:369.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Santarosa M, Del Col L, Viel A, Bivi N, D’Ambrosio C, Scaloni A, et al. BRCA1 modulates the expression of hnRNPA2B1 and KHSRP. Cell Cycle. 2010;9(23):4666–73.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chou CF, Mulky A, Maitra S, Lin WJ, Gherzi R, Kappes J, et al. Tethering KSRP, a decay-promoting AU-rich element-binding protein, to mRNAs elicits mRNA decay. Mol Cell Biol. 2006;26(10):3695–706.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Liu Y, Wang Y, Cheng C, Chen Y, Shi S, Qin J, et al. A relationship between p27(kip1) and Skp2 after adult brain injury: implications for glial proliferation. J Neurotrauma. 2010;27(2):361–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Tao T, Cheng C, Ji Y, Xu G, Zhang J, Zhang L, et al. Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell. 2012;23(14):2635–44.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One. 2013;8(5), e63404.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3(4):447–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Gherzi R, Trabucchi M, Ponassi M, Ruggiero T, Corte G, Moroni C, et al. The RNA-binding protein KSRP promotes decay of beta-catenin mRNA and is inactivated by PI3K-AKT signaling. PLoS Biol. 2006;5(1), e5.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14(4):8213–27.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bai X, Wang J, Zhang L, Ma J, Zhang H, Xia S, et al. Prostaglandin E(2) receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol. 2013;42(5):1833–41.PubMedGoogle Scholar
  33. 33.
    Suswam EA, Nabors LB, Huang Y, Yang X, King PH. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer. 2005;113(6):911–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24(26):4281–92.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Ying-Ying Wang
    • 1
  • Xiao-Ling Gu
    • 2
  • Chao Wang
    • 1
  • Hua Wang
    • 4
  • Qi-Chao Ni
    • 4
  • Chun-Hui Zhang
    • 4
  • Xia-Fei Yu
    • 4
  • Li-Yi Yang
    • 4
  • Zhi-Xian He
    • 4
  • Guo-Xin Mao
    • 2
  • Shu-Yun Yang
    • 3
  1. 1.Department of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Inflammation and Molecular Drug TargetNantong UniversityNantongChina
  2. 2.Department of OncologyAffiliated Hospital of Nantong UniversityNantongChina
  3. 3.Department of PathologyNantong University Cancer Hospital, Nantong UniversityNantongChina
  4. 4.Department of General SurgeryThe Affiliated Hospital of Nantong UniversityNantongChina

Personalised recommendations